科研成果 |
1.代表性论著（部分文章，通讯作者注上标“*”） (1) Huang P, Cheng H, Ji J, Zhang W, Ma J, Wei D, Ren L（*）. LncRNA Miat knockdown enhances pirarubicin-mediated anticancer sensitivity in breast cancer cells. Environ Toxicol. 2023 Online ahead of print. (2) Huang P, Zhang W, Ji J, Ma J, Cheng H, Qin M, Wei D, Ren L（*）. LncRNA Miat knockdown protects against pirarubicin-induced cardiotoxicity by targeting miRNA-129-1-3p. Environ Toxicol. 2023 Online ahead of print. (3) Huang P, Zhang Y, Wang F, Qin M, Ma J, Ji J, Wei D, Ren L（*）. MiR-494-3p aggravates pirarubicin-induced cardiomyocyte injury by regulating MDM4/p53 signaling pathway. Environ Toxicol. Online ahead of print. (4) Ma J, Chen C, Fan Z, Zhang Y, Ji J, Wei D, Zhang F, Sun B, Huang P, Ren L（*）. CircEGFR reduces the sensitivity of pirarubicin and regulates the malignant progression of triple-negative breast cancer via the miR-1299/EGFR axis. Int J Biol Macromol. 2023 31;244:125295. (5) Huang P, Wang F, Zhang Y, Zhang Y, Qin M, Ji J, Wei D, Ren L（*）. Icariin alleviates atherosclerosis by regulating the miR-205-5p/ERBB4/AKT signaling pathway. Int Immunopharmacol. 2023 ;114:109611. (6) Ma J, Wang F, Chen C, Ji J, Huang P, Wei D, Zhang Y, Ren L（*）. Identification of prognostic genes signature and construction of ceRNA network in pirarubicin treatment of triple-negative breast cancer. Breast Cancer. 2023 ;30(3):379-392. (7) Zhang Y, Ma J, Liu S, Chen C, Li Q, Qin M, Ren L（*）. Ginsenoside F1 attenuates pirarubicin-induced cardiotoxicity by modulating Nrf2 and AKT/Bcl-2 signaling pathways. J Ginseng Res. 2023;47(1):106-116. (8) Ma J, Chen C, Liu S, Ji J, Wu D, Huang P, Wei D, Fan Z, Ren L（*）. Identification of a five genes prognosis signature for triple-negative breast cancer using multi-omics methods and bioinformatics analysis. Cancer Gene Ther. 2022 ;29(11):1578-1589. (9) Huang P, Zhang Y, Wang F, Qin M, Ren L（*）. MiRNA-205-5p regulates the ERBB4/AKT signaling pathway to inhibit the proliferation and migration of HAVSMCs induced by ox-LDL. Pathol Res Pract. 2022 ;233:153858. (10) Zhang Y, Liu S, Ma JL, Chen C, Huang P, Ji JH, Wu D, Ren LQ（*）. Apocynum venetum leaf extract alleviated doxorubicin-induced cardiotoxicity through the AKT/Bcl-2 signaling pathway. Phytomedicine. 2022. 94:153815. (11) Zhang Y, Li Q, Xu D, Li T, Gu Z, Huang P, Ren L（*）. Idarubicin-induced oxidative stress and apoptosis in cardiomyocytes: An in vitro molecular approach. Hum Exp Toxicol. 2021;40(12_suppl):S553-S562. (12) Li Q, Xu D, Gu Z, Li T, Huang P, Ren L（*）. Rutin restrains the growth and metastasis of mouse breast cancer cells by regulating the microRNA-129-1-3p-mediated calcium signaling pathway. J Biochem Mol Toxicol. 2021;35(7):e22794. (13) Zhang Y, Xu D, Huang P, Zhang Y, Li Q, Fan Z, Ren L（*）. Essential role of protein kinase C βI in icariin-mediated protection against atherosclerosis. J Pharm Pharmacol. 2021 12;73(9):1169-1179. (14) Qin M, Li Q, Wang Y, Li T, Gu Z, Huang P, Ren L（*）. Rutin treats myocardial damage caused by pirarubicin via regulating miR-22-5p-regulated RAP1/ERK signaling pathway. J Biochem Mol Toxicol. 2021;35(1):e22615. (15) Liu S, Xu DS, Ma JL, Huang P, Wu D, Ren LQ（*）. LncRNA H19 Mitigates Oxidized Low-Density Lipoprotein Induced Pyroptosis via Caspase-1 in Raw 264.7 Cells. Inflammation. 2021;44(6):2407-2418. (16)Li Q, Qin M, Li T, Gu Z, Tan Q, Huang P, Ren L（*）. Rutin protects against pirarubicin-induced cardiotoxicity by adjusting microRNA-125b-1-3p-mediated JunD signaling pathway. Mol Cell Biochem. 2020;466(1-2):139-148. (17) Zhang Y, Ma XY, Zhang T, Qin M, Sun B, Li Q, Hu DW, Ren LQ（*）. Protective Effects of Apocynum venetum Against Pirarubicin-Induced Cardiotoxicity. Am J Chin Med. 2019. 47(5):1. (18) Lou X, Ma X, Wang D, Li X, Sun B, Zhang T, Qin M, Ren L（*）. Systematic analysis of long non-coding RNA and mRNA expression changes in ApoE-deficient mice during atherosclerosis. Mol Cell Biochem. 2019;462(1-2):61-73. (19) Zhang Y, Li M, Li X, Zhang T, Qin M, Ren L（*）. Isoquinoline Alkaloids and Indole Alkaloids Attenuate Aortic Atherosclerosis in Apolipoprotein E Deficient Mice: A Systematic Review and Meta-Analysis. Front Pharmacol. 2018 5;9:602. 075-1097. (20) Mu XP, Ren LQ, Yan HW, Zhang XM, Xu TM, Wei AH（*）, Jiang JL（*）. Enhanced differentiation of human amniotic fluid-derived stem cells into insulin-producing cells in vitro. J Diabetes Investig. 2017;8(1):34-43. 2.主持或参加科研项目（课题）情况（按时间倒序排序） 1.国家自然科学基金面上项目，82273924，基于lncRNA MIAT/miR-129-1-3P/GRIN2D调控机制探讨芦丁减轻吡柔比星所致心脏毒性并增敏吡柔比星抗乳腺癌的作用，51万元，2022/01-2025/12，在研，主持 2.吉林省科技厅科技发展计划项目，20220204046YY，长白山蝮蛇油纳米乳载体的制备及相关化妆品的开发，2022/01 - 2025/12，50万元，在研，主持 3.国家自然科学基金面上项目，81773934，基于FKN/Syk/p38MAPK信号通路研究淫羊藿苷抗动脉粥样硬化作用及microRNA调控机制，2018/01 - 2021/12，59万元，在研，主持 4.吉林省科技发展计划项目，20180311029YY，“罗布麻叶降脂胶囊”的产业化开发，2018/01/01-2020/12/31，100万元，在研，主持 5.吉林省省级产业创新专项资金项目，2018C047-4，长白山白眉蝮蛇蛇毒精制技术研究与开发，2018/01-2019/12，25万元，在研，主持 6.吉林省科技厅重大科技攻关项目，20150204015YY，罗布麻叶总黄酮抗动脉粥样硬化作用药效学研究，2015/01-2017/12，18万元，已结题，主持 7.吉林省自然科学基金项目，20150101221JC，基于NF-κB炎症相关信号通路的淫羊藿总黄酮及淫羊藿苷抗动脉粥样硬化机制研究，2015/01-2017/12，10万元，已结题，参加 8.长春市科技局技攻关项目，14KG048，中药6类新药复方鹿角乳痛宁胶囊，2014/12-2016/12，30万元，已结题，主持 9.吉林省科技厅医药产业发展专项项目，YYZX201239，鹿角纳米粉体乳痛宁的产业化开发，2012/07-2015/10，50万元，已结题，参加 10.教育部博士点基金项目，200801830050，低硒、低维生素E对克山病心肌重构的影响及分子机制，2009/01-2011/12，6万元，已结题，主持 11.国家自然科学基金面上项目，30872194，膳食低硒、低维生素E对克山病心肌纤维化和心肌重构的影响及其分子机制，2009/01-2009/12，8万元，已结题，主持 12.国家教委之留学归国人员启动基金项目，363，同型半胱氨酸对动脉平滑肌细胞胶原基因表达的影响，1999/01-2002/12，3万元，已结题，主持 13.国家自然科学基金面上项目，H2818，蒙药乳腺-I号干预下大鼠乳腺增生模型E2信号传导通路的相关蛋白研究，1999/01-2001/12，30万元，已结题，参加 14.国家自然科学基金面上项目，39870668，肠道病毒感染及其基因变异在克山病发病中的作用研究，1999/01-2001/12，11万元，已结题，参加 15.国家自然科学基金面上项目，39730390，氟中毒（地氟病）发病机理，1998/01-2001/12，82万元，已结题，参加 16.国家自然科学基金面上项目，39470612，硒和维生素E对胰岛细胞保护作用的研究，1995/01-1997/12，6.5万元，已结题，参加 |
